Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A phase I double-blind trial investigating trachoma vaccine regimens using the Chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02)

Pollock K., (2024), The Lancet Infectious Diseases

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.

Thwaites RS. et al, (2023), Nat Commun, 14

Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.

Liu Z. et al, (2023), J Crohns Colitis

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

Liu Z. et al, (2023), eClinicalMedicine, 64

Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.

Khan M. et al, (2023), Open Forum Infect Dis, 10

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Writing Committee for the REMAP-CAP Investigators None. et al, (2023), JAMA, 329, 1183 - 1196

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Szubert AJ. et al, (2023), eClinicalMedicine, 56

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

Liu Z. et al, (2023), Lancet Gastroenterol Hepatol, 8, 145 - 156

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

An experimental medicine study of seasonal influenza vaccination responses in Lymph nodE single-cell Genomics in AnCestrY (LEGACY01) v1

M Pollock K., (2023)

LEGACY01: ADVERSE EVENTS v1

M Pollock K., (2023)

LEGACY01: ASSESSMENT AND FOLLOW-UP v1

M Pollock K., (2023)

LEGACY01: DATA AND SAMPLE SHARING v1

M Pollock K., (2023)

LEGACY01: PARTICIPANT ENTRY v1

M Pollock K., (2023)

LEGACY01: QUALITY ASSURANCE AND CONTROL v1

M Pollock K., (2023)

LEGACY01: REGULATORY ISSUES v1

M Pollock K., (2023)

LEGACY01: STATISTICS AND DATA ANALYSIS v1

M Pollock K., (2023)

LEGACY01: STUDY DESIGN v1

M Pollock K., (2023)

LEGACY01: STUDY MANAGEMENT v1

M Pollock K., (2023)

Load More

Include forthcoming?